Bayer AG brought in a new sales team specifically to promote Kerendia (finerenone) in the US for chronic kidney disease (CKD) in patients with type 2 diabetes, and those representatives will hit the ground running later this month. The US Food and Drug Administration approved the non-steroidal mineralocorticoid receptor antagonist on 9 July and the company is working to manufacture enough of the once-daily pills to distribute the product to retail pharmacies within the next two weeks.
Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal...
